Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
@article{Choi2015ErratumAP, title={Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease}, author={J. Choi and B. Lee and J. M. Ko and Y. B. Sohn and Jin-Sung Lee and Gu-Hwan Kim and S. Heo and June-Young Park and Y. Kim and Ja-Hye Kim and Han-Wook Yoo}, journal={Journal of Korean Medical Science}, year={2015}, volume={30}, pages={1373 - 1373} }
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. pISSN 1011-8934 eISSN 1598-6357 http://dx.doi.org/10.3346/jkms.2015.30.9.1373 • J Korean Med Sci 2015; 30: 1373 CORRESPONDENCE
Topics from this paper
2 Citations
The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
- Medicine
- American journal of hematology
- 2019
Recent advances and future challenges in Gaucher disease.
- Medicine
- Blood cells, molecules & diseases
- 2018
- 6